Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713518 · ClinicalTrials.gov registry record · Phase 2
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00713518 is a Phase 2 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 152 participants.
The verdict
NCT00713518, a Phase 2 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
Interventions
- DRUG 0.5 mg ranibizumab
- DRUG 3 mg PF-04523655
- DRUG 1 mg PF-04523655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713518
The ClinicalTrials.gov registry entry for NCT00713518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 0.5 mg ranibizumab is the first listed.
NCT00713518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00713518 about?
NCT00713518 is a clinical study titled "Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).". The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
What is the current status of trial NCT00713518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2009-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00713518?
The interventions under investigation include: 0.5 mg ranibizumab (DRUG), 3 mg PF-04523655 (DRUG), 1 mg PF-04523655 (DRUG).
Who is sponsoring clinical trial NCT00713518?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.